Abstract: Objective：To explore serum human epididymis protein 4 （HE4），cancer antigen 125 （CA125） for uterine endometrial cancer risk assessment. Methods：With electroluminescent assay in 453 patients with myoma of uterus，126 cases of adenomyosis，26 cases of endometrial hyperplasia patients，10 cases of endometrial polyps patients，212 cases of endometrial cancer patients and 72 cases of healthy women of serum HE4 and CA125 levels. Results：The serum level of HE4 expression in endometrial carcinoma were higher than that of the other groups，the difference was statistically significant （P＜0.01）. The serum level of CA125 expression in adenomyosis were higher than that of the other groups，the difference was statistically significant （P=0.000）. Endometrial carcinoma patients serum HE4 expression level and FIGO stag were a significant positive correlation （rs=0.538，P=0.000）. HE4 and CA125 combined detection of endometrial cancer sensitivity were higher than single HE4 detection sensitivity. Conclusions：Single serum HE4 and CA125 detection has a certain significance to the early diagnosis，staging and prognosis of endometrial carcinoma，which can be used as an important index for the diagnosis of endometrial cancer.

Key words: Endometrial neoplasms, CA-125 antigen, Diagnosis, Human epididymis protein 4